Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares were down 6.5% on Monday . The company traded as low as $17.01 and last traded at $17.09. Approximately 829,540 shares changed hands during trading, a decline of 37% from the average daily volume of 1,317,589 shares. The stock had previously closed at $18.27.

A number of research analysts have weighed in on IRWD shares. HC Wainwright set a $13.00 target price on Ironwood Pharmaceuticals and gave the company a “sell” rating in a report on Wednesday, August 22nd. ValuEngine raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. Wells Fargo & Co lifted their target price on Ironwood Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, May 31st. Cowen reaffirmed a “market perform” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, July 18th. Finally, BidaskClub raised Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, July 6th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $19.00.

The stock has a market cap of $2.65 billion, a PE ratio of -18.67 and a beta of 0.77. The company has a quick ratio of 2.93, a current ratio of 2.94 and a debt-to-equity ratio of -8.64.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.09). The business had revenue of $81.10 million for the quarter, compared to the consensus estimate of $82.61 million. Ironwood Pharmaceuticals had a negative net margin of 34.03% and a negative return on equity of 2,073.20%. The business’s revenue was up 24.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.28) EPS. equities analysts expect that Ironwood Pharmaceuticals, Inc. will post -0.82 earnings per share for the current year.

In other news, insider Thomas A. Mccourt sold 30,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Friday, July 6th. The stock was sold at an average price of $20.00, for a total transaction of $600,000.00. Following the completion of the sale, the insider now owns 30,000 shares in the company, valued at approximately $600,000. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Halley E. Gilbert sold 29,551 shares of Ironwood Pharmaceuticals stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $19.75, for a total value of $583,632.25. Following the sale, the insider now owns 29,551 shares of the company’s stock, valued at approximately $583,632.25. The disclosure for this sale can be found here. In the last quarter, insiders have sold 191,239 shares of company stock valued at $3,614,206. Corporate insiders own 7.63% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at about $138,000. Meeder Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $186,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at about $180,000. A.R.T. Advisors LLC bought a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $208,000. Finally, V Wealth Management LLC bought a new stake in Ironwood Pharmaceuticals in the 2nd quarter worth approximately $258,000. Hedge funds and other institutional investors own 96.94% of the company’s stock.

Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Recommended Story: Investing in Dividend Stocks

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.